Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 3,447 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neoplasms,Colorectal Clear all
Active, not recruiting Phase 2 Interventional

Botensilimab and Balstilimab Optimization in Colorectal Cancer

NCT06268015
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Botensilimab, Balstilimab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab, Panitumumab
Drug
Lead sponsor
Nicholas DeVito, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 27, 2026, 2:50 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

NCT05710406
View directory record Official record
Conditions
Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
Interventions
Encorafenib, Cetuximab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Patient Observation
Drug · Biological · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
202
States / cities
Millville, Delaware • Newark, Delaware • Rehoboth Beach, Delaware + 159 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 27, 2026, 2:50 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626
View directory record Official record
Conditions
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions
STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
Drug · Combination Product
Lead sponsor
Marengo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Sacramento, California • Celebration, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 27, 2026, 2:50 PM EDT
Completed No phase listed Observational

Diffusion-Weighted MRI for Liver Metastasis

NCT02781935
View directory record Official record
Conditions
Colorectal Cancer, Colon Cancer Liver Metastasis, Malignant Neoplasm of Rectum Metastatic to Liver
Interventions
DW-MRI
Procedure
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 27, 2026, 2:50 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

L-Menthol Injection as a Novel Technique During Colonoscopy

NCT02588248
View directory record Official record
Conditions
Colonic Polyps, Colon Cancer
Interventions
Peppermint Oil, Placebo
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
45 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 27, 2026, 2:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ellagic Acid, Urolithin and Colonic Microbial Communities Affected by Walnut Consumption

NCT04066816
View directory record Official record
Conditions
Colo-rectal Cancer, Colon Cancer, Diet Habit
Interventions
Walnuts
Other
Lead sponsor
UConn Health
Other
Eligibility
50 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 27, 2026, 2:50 PM EDT
Recruiting Not applicable Interventional

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

NCT04751435
View directory record Official record
Conditions
Educational Materials for Genetic Testing, Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer
Interventions
Cognitive interview, LCAM intervention, Standard of care
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Brooklyn, New York • Jamaica, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer

NCT02138617
View directory record Official record
Conditions
Colon Cancer
Interventions
5-Fluorouracil, Leucovorin, Irinotecan, Bevacizumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
7
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 27, 2026, 2:50 PM EDT
Completed Phase 1 Interventional

Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

NCT01294826
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions
AUY922, Cetuximab
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 27, 2026, 2:50 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

NCT07292298
View directory record Official record
Conditions
Rectal Adenocarcinoma, Rectal Cancer
Interventions
High Rare Dose Rectal Brachytherapy Boost
Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Aurora, Colorado • Rochester, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 2:50 PM EDT
Terminated Phase 1 Interventional

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

NCT04348916
View directory record Official record
Conditions
Cancer, Melanoma, Solid Tumor, Squamous Cell Carcinoma of Head and Neck, Breast Cancer, Advanced Solid Tumor, Triple Negative Breast Cancer, Colorectal Carcinoma, Non-melanoma Skin Cancer, Liver Metastases
Interventions
ONCR-177, pembrolizumab
Biological
Lead sponsor
Oncorus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Duarte, California • Denver, Colorado • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 27, 2026, 2:50 PM EDT
Completed Not applicable Interventional

Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children

NCT02129049
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Colon Cancer, Leukemia, Lymphoma, Malignant Neoplasm, Melanoma, Rectal Cancer
Interventions
educational intervention, telephone-based intervention, questionnaire administration
Other · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
11
States / cities
Bozeman, Montana • Kennewick, Washington • Kirkland, Washington + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 27, 2026, 2:50 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Ohio State University (OSU) SCREEN Community Program

NCT06666192
View directory record Official record
Conditions
Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma
Interventions
Cancer Screening, Discussion, Educational Activity, Educational Intervention, Focus Group, Health Care Delivery, Health Promotion, Health Promotion and Education, Health Risk Assessment, Implementation, Informational Intervention, Internet-Based Intervention, Interview, Outreach, Patient Navigation, Survey Administration
Other · Behavioral · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
2,067 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 27, 2026, 2:50 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

NCT00040599
View directory record Official record
Conditions
Colorectal Cancer, Colon Cancer, Rectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumor
Interventions
hMN14 (labetuzumab)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
5
States / cities
Newport Beach, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 27, 2026, 2:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Colorectal Cancer Screening Navigator Program for Low Income and Non-English Speaking Populations

NCT00476970
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Patient Navigation
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
52 Years to 79 Years
Enrollment
1,223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chelsea, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Oct 27, 2026, 2:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community Dissemination of an Evidence-based Colorectal Cancer (CRC) Screening Intervention

NCT01351220
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Educational program and FOBT kits, Educational program and FOBT kits, and technical assistance
Behavioral
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
50 Years to 75 Years
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 27, 2026, 2:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Sustainable Approach to Increasing Cancer Screening

NCT01395459
View directory record Official record
Conditions
Colorectal Cancer, Breast Cancer, Cervical Cancer
Interventions
IVR only, IVR+PCC
Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
21 Years to 86 Years
Enrollment
13,675 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 27, 2026, 2:50 PM EDT
Recruiting Phase 2 Interventional

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

NCT07223424
View directory record Official record
Conditions
Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC), Hepatocellular Carcinoma, Ulcerative Colitis, Esophageal Cancer, Squamous Cell Carcinoma, Gastric/GEJ, Cervical Cancer, Gastro-Esophageal Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
nivolumab, pembrolizumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 27, 2026, 2:50 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Microbiome in Colorectal Cancer Onset and Progression

NCT05368688
View directory record Official record
Conditions
Colorectal Cancer, Tumor, CRC, GI Cancer, Gastrointestinal Cancer
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
50 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 27, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer

NCT00112918
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Bevacizumab, Capecitabine, 5-Fluorouracil (5-FU), Leucovorin calcium, Oxaliplatin
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
3,451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Oct 27, 2026, 2:50 PM EDT
Completed Phase 1 Interventional

A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer

NCT03031691
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
brontictuzumab, trifluridine/tipiracil
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Denver, Colorado • Miami, Florida • Sarasota, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 27, 2026, 2:50 PM EDT
Completed No phase listed Observational

Pain in Cancer Survivors

NCT00581724
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Prostate Cancer, Head and Neck Cancer, Lung Cancer
Interventions
Telephone interview or self report survey.
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 27, 2026, 2:50 PM EDT
Completed Phase 1Phase 2 Interventional

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

NCT02335918
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
Interventions
Combination of varlilumab and nivolumab
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 27, 2026, 2:50 PM EDT
Completed Phase 1 Interventional

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

NCT03841110
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
Interventions
FT500, Nivolumab, Pembrolizumab, Atezolizumab, Cyclophosphamide, Fludarabine, IL-2
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 27, 2026, 2:50 PM EDT